Promising targets and drugs in rheumatoid arthritis: a module-based and cumulatively scoring approach. Issue 8 (1st August 2020)

• Record Type: Journal Article
• Authors: Li, Xingyan; Yang, Yejing; Sun, Guili; Dai, Wanwu; Jie, Xuri; Du, Yongjun; Huang, Runjie; Zhang, Jiaming
• Is Part Of: Bone & joint research. Volume 9:Issue 8(2020)
• Page Start: 501
• Page End: 514
• Publication Date: 2020-08-01
• Subjects: Rheumatoid arthritis -- Weighted gene co-expression network -- Target -- Drug screening; Musculoskeletal system -- Periodicals; 573.705
• DOI: 10.1302/2046-3758.98.BJR-2019-0301.R1
• Languages: English
• ISSNs: 2046-3758

Abstract

Abstract : Aims: Rheumatoid arthritis (RA) is a systematic autoimmune disorder, characterized by synovial inflammation, bone and cartilage destruction, and disease involvement in multiple organs. Although numerous drugs are employed in RA treatment, some respond little and suffer from severe side effects. This study aimed to screen the candidate therapeutic targets and promising drugs in a novel method. Methods: We developed a module-based and cumulatively scoring approach that is a deeper-layer application of weighted gene co-expression network (WGCNA) and connectivity map (CMap) based on the high-throughput datasets. Results: Four noteworthy RA-related modules were identified, revealing the immune- and infection-related biological processes and pathways involved in RA. HLA-DMA, HLA-DMB, HLA-DPA1, HLA-DPB1, HLA-DQB1, HLA-DRA, HLA-DRB1, BLNK, BTK, CD3D, CD4, IL2RG, INPP5D, LCK, PTPRC, RAC2, SYK, and VAV1 were recognized as the key hub genes with high connectivity in gene regulation networks and gene pathway networks. Moreover, the long noncoding RNAs (lncRNAs) in the RA-related modules, such as FAM30A and NEAT1, were identified as the indispensable interactors with the hub genes. Finally, candidate drugs were screened by developing a cumulatively scoring approach based on the selected modules. Niclosamide and the other compounds of T-type calcium channel blocker, IKK inhibitor, and PKC activator, HIF activator, and proteasome inhibitor, which harbour the similar gene signature with niclosamide, were promising drugs with high specificity and broad coverage for the RA-related modules. Conclusion: This study provides not only the promising targets and drugs for RA but also a novel methodological insight into the target and drug screening. Cite this article: Bone Joint Res 2020;9(8):501–514.